KPV

The Part of the Hormone That Talks to the Receptor Is Not in KPV

UKPWritten and published by UK Peptides4 min readUpdated 4 cited sources

The short answer

Melanocortin receptor activation depends on a His-Phe-Arg-Trp core within alpha-MSH, and that tetrapeptide alone is a nanomolar agonist. KPV is the C-terminal tripeptide and contains none of those residues, which is a strong structural reason to doubt that it acts at melanocortin receptors.

Key facts

alpha-MSH sequence positions
13 residues, acetylated N-terminus, amidated C-terminus
Receptor message core
His-Phe-Arg-Trp, residues 6-9
KPV position in the parent
Residues 11-13
Overlap between the two
None
Core tetrapeptide potency
Nanomolar at MC4 and MC5 in reported derivatives
KPV PubChem CID
125672
KPV molecular weight
342.43 g/mol
KPV formula
C16H30N4O4

The claim worth checking

KPV is very often described as the anti-inflammatory part of alpha-MSH, with the implication that it works the way the parent hormone works, by activating melanocortin receptors. That implication is testable against the structure-activity literature for those receptors, and it does not survive the test. The reason needs setting out carefully, because the alternative explanation is that KPV does something by a different route entirely, not that it does nothing.

Where the receptor activity lives in alpha-MSH

Structure-activity work on the melanocortin receptors converged long ago on a short internal sequence, His-Phe-Arg-Trp, as the element required for receptor molecular recognition and stimulation. It is not merely necessary but largely sufficient: capped tetrapeptides built on the His-D-Phe-Arg-Trp-NH2 template are agonists at melanocortin receptors in their own right, and Holder and colleagues reported derivatives of that tetrapeptide with EC50 values in the sub-nanomolar to nanomolar range at MC4 and MC5, in one case fourteen-fold more potent than alpha-MSH itself at the mouse MC4 receptor. A four-residue fragment that outperforms the full hormone is about as clear a demonstration as pharmacology offers that this is where the receptor interaction resides.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

Where KPV sits, and what it therefore lacks

alpha-MSH is thirteen residues. The His-Phe-Arg-Trp core occupies positions 6 to 9. KPV is Lys-Pro-Val, positions 11 to 13, the C-terminal tail. There is no overlap. KPV contains no histidine, no phenylalanine, no arginine and no tryptophan, so none of the four residues that the receptor literature identifies as the pharmacophore. It is not a truncation of the active site; it is a different part of the molecule.

What that means for how KPV is described

It means the common description is wrong in its mechanism even where it may be right about the observation. If KPV has anti-inflammatory activity in a model, the melanocortin receptors are not the obvious explanation and there is no evidence putting them in the frame. The evidence that does exist points somewhere quite different: PepT1 carries KPV into the cell, and the effects reported are on intracellular signalling (NF-kappaB and MAP kinase) rather than on a surface receptor. An intracellular, transporter-dependent mechanism and a cell-surface receptor mechanism are not variations on a theme. Describing KPV as a melanocortin agonist attributes to it a pharmacology it has not been shown to have.

The honest limits of a structural argument

Absence of the known pharmacophore is a strong reason to doubt receptor activity, not a proof of its absence. Receptors sometimes have secondary binding sites, and a compound can modulate a receptor without engaging its orthosteric pocket. What can be said with confidence is narrower and still useful: no published work demonstrates KPV activating a melanocortin receptor, the sequence gives a clear structural reason not to expect it, and the mechanism that has been tested experimentally is a different one. Anyone asserting the receptor mechanism should be asked for the binding or functional data, because it does not appear to exist.

Why the distinction is worth the space

Because it changes what the molecule is and what would count as evidence about it. If KPV were a melanocortin agonist, the relevant comparators would be other melanocortin ligands and the relevant safety questions would be those of that class. It is not, on current evidence. It is a tripeptide whose measurable property is that a nutrient transporter carries it into cells. Those are different molecules to think about, and only one of them matches what has actually been published.

Quick reference

His-Phe-Arg-Trp coreKPV
Position in alpha-MSHResidues 6-9Residues 11-13
Melanocortin receptor agonismDemonstrated, nanomolarNot demonstrated
Overlap with the otherNoneNone
Proposed route of actionCell-surface receptorPepT1 transport, intracellular
Reported readoutsReceptor EC50NF-kappaB, MAP kinase signalling

Frequently asked questions

So does KPV do nothing?

That is not the argument. There is a body of cell and animal work reporting effects, and a mechanism that has been tested with competition, labelled uptake and a genetic knockout. The mechanism is transport into the cell rather than activation of a melanocortin receptor, and the two get conflated constantly.

Could KPV still bind a melanocortin receptor weakly?

It is not excluded, but nothing published demonstrates it and the structure gives no reason to expect it. A claim that specific needs data behind it, and the absence of the entire recognition motif is a substantial obstacle.

Why is the C-terminal fragment the one that gets attention then?

Because the anti-inflammatory activity attributed to alpha-MSH was mapped to the C-terminal region rather than the pigmentation-relevant core, and because a tripeptide is far easier to make and to handle than a thirteen-residue hormone. Neither reason has anything to do with receptor pharmacology.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.